Who are Asclera's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): talc powder, Talc Slurry Pleurodesis, Ethyl alcohol, Foam sclerotherapy, Varithena®, sclerotherapy with aethoxysclerol foam.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/polidocanol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Asclera — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Asclera (POLIDOCANOL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sclerosing Agent [EPC]. Area: Hematology.

marketed Sclerosing Agent [EPC] Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Asclera (POLIDOCANOL) — Provensis. Asclera works by causing inflammation and scarring in targeted veins, leading to their closure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Asclera TARGET	POLIDOCANOL	Provensis	marketed	Sclerosing Agent [EPC]		2010-01-01
talc powder	talc powder	Chinese University of Hong Kong	marketed	Sclerosing agent
Talc Slurry Pleurodesis	Talc Slurry Pleurodesis	Memorial Healthcare System	marketed	Sclerosing agent
Ethyl alcohol	Ethyl alcohol	South Egypt Cancer Institute	marketed	Cytotoxic agent / Sclerosing agent
Foam sclerotherapy	Foam sclerotherapy	Imperial College London	marketed	Sclerosing agent
Varithena®	Varithena®	Boston Scientific Corporation	marketed	Sclerosing agent	Vein endothelium (non-receptor mediated tissue damage)
sclerotherapy with aethoxysclerol foam	sclerotherapy with aethoxysclerol foam	Medical University of Vienna	marketed	Sclerosing agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sclerosing Agent [EPC] class)

Provensis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Asclera — Competitive Intelligence Brief. https://druglandscape.com/ci/polidocanol. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab